复星医药(02196.HK)：子公司“注射用HLX43”获药品临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a new treatment regimen for advanced solid tumors, which includes HLX43 and HLX07 [1] Group 1 - The approved treatment regimen consists of HLX43, a PD-L1 targeted antibody conjugate, and HLX07, a recombinant humanized monoclonal antibody targeting EGFR, both classified as Class 1 therapeutic biological products [1] - The clinical trials for this treatment plan will be conducted in China, with Phase II studies planned once conditions are met [1] - The regimen also includes the use of Surufatinib injection, marketed in China under the name Hansizhuang® [1]